Játiva, Spain

  • Study of Bulevirtide in Participants With Chronic Hepatitis D Infection

    The study design time perspective is retrospective and prospective for participants who previously participated in MYR-Reg-02 and are currently receiving BLV and prospective for participants who are scheduled to receive BLV.

    Phase

    N/A

    Span

    251 weeks

    Sponsor

    Gilead Sciences

    Hall in Tirol

    Recruiting

1-1 of 1